Most recent update: Tuesday, April 7, 2020 - 09:55

Bariatric News - Cookies & privacy policy

You are here


Scientists seek volunteers to trial drug to combat obesity

Researchers are looking for volunteers to trial a revolutionary new drug to combat obesity. The capsule has been laboratory-tested on human tissue for more than four years by scientists at Queen Mary University of London, UK, in a project part-funded by the charity Bowel & Cancer Research. The capsule, packed with a mix of natural oils, is believed to ‘trick’ the gut into thinking it’s full and suppresses appetite. Researchers believe it could reduce the need for bariatric surgery and help solve the obesity crisis.  

XOMA 358 granted ODD for congenital hyperinsulinism

XOMA has been granted Orphan Drug Designation (ODD) by the FDA for XOMA 358, a fully human allosteric monoclonal antibody that reduces both the binding of insulin to its receptor and downstream insulin signalling, for the treatment of congenital hyperinsulinism (HI). XOMA 358, the lead antibody in the company’s XMetD program (designed to deactivate the insulin receptor), is a fully human allosteric monoclonal antibody that binds to insulin receptors and attenuates insulin action.

Parasite drug used to combat type 2 diabetes

Researchers from Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, have revealed that a modified form of a different drug, niclosamide, may hold the key to battling the type 2 diabetes at its source. Niclosamide is currently used to eliminate intestinal parasites.

The study, led by Dr Victor Shengkan Jin, an associate professor of pharmacology at Rutgers, is published online by the journal Nature Medicine.

BioKier gains funding to develop gastric bypass drug

BioKier, a privately held development-stage pharmaceutical company focused on the treatment of diabetes, has finalised a funding commitment of US$1.7 million from Broadview Ventures and the American Heart Association’s Science & Technology Accelerator Program. 

How the body responds to T2DM drug treatment

Researchers at Lund University in Sweden have developed a new mouse model which they claim answers some of the questions of what actually happens in the body when type 2 diabetes develops and how the body responds to drug treatment.

Liraglutide induces some weight loss, diabetes resolution

Clinical results from a phase 3a clinical trial have shown that liraglutide has led to a modest weight and metabolic improvement in obese diabetics over the course of a year.

The SCALE Diabetes trial, instigated by Danish pharmaceutical company Novo Nordisk, found that a daily treatment of liraglutide 3mg led to a 6% weight loss over 56 weeks, compared to 5% for a 1.8mg treatment and 2% for a placebo.

Bariatric patients at risk of substance abuse post-surgery

Bariatric patients may be at risk of increased drug, alcohol and tobacco use following surgery, according to a new report published in the Archives of Surgery.

Subscribe to RSS - drug